Could inhaled corticosteroids be the game changers in the prevention of severe COVID-19? A review of current evidence

Abstract

The final version may contain major or minor changes.Subscription: Information about subscribing to Minerva Medica journals is online at: http://www.minervamedica.it/en/how-to-order-journals.php Reprints and permissions: For information about reprints and permissions send an email to:

The Challenges of COVID-19 with Obesity-Related Cancers

“…After screening 283 abstracts generated by the search algorithm, 10 studies were deemed eligible for inclusion in the final quantitative analysis (Figure 1). In total, 26,808 patients were incorporated in the analysis (19,152 in the pre-pandemic cohort and 7656 in the pandemic cohort), with five studies being from east Asia (one from Japan [14], two from China [15,16], and two from Korea [17,18]) and the remaining five from Europe (two from the United Kingdom [11,19], one from Italy [20], one from Ireland [3], and one from Serbia [21]). The size of the pandemic cohorts in each study was compared to that of the pre-pandemic cohorts after matching for the time duration of the data collection in the pandemic cohorts (in months).…”

“…Although broadly applied vaccination programs have been and continue to constitute the mainstay of strategies to counter the COVID-19 pandemic, there has been a continuing worldwide effort for the development of drug therapies against the SARS-CoV-2 infection, either through the development of new agents or through repurposing already available drugs marketed for other indications [152,153]. Certain national recommendations for the treatment of the SARS-CoV-2 infection according to its severity take into account the comorbidity background of affected patients to guide and possibly escalate medical management [154,155].…”

Perspectives in vaccines, immune response, therapeutic interventions and COVID-19

“…In this context, much research has been conducted on biomarkers in sepsis and biomarkers in severe COVID-19 [ 42 , 43 , 44 , 45 , 46 , 47 , 48 ]. Accordingly, new treatments as well as repurposed drugs have been proposed and tested against COVID-19 [ 49 , 50 , 51 , 52 ]. Vallianou and colleagues reviewed current and under development drugs for the treatment of COVID-19, also presenting the future perspectives for new drugs from the study of various therapeutic targets [ 53 ].…”